Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending‐dose study-Reference-Cited by-同舟云学术

Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending‐dose study

Published:2019-08-09 Issue:10 Volume:85 Page:2302-2309
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Small David¹,Ferguson‐Sells Lisa¹,Dahdah Nagib²,Bonnet Damien³,Landry John⁴,Li Baohui¹^ORCID

Affiliation:

1. Eli Lilly and Company Indianapolis IN USA

2. CHU Ste‐JustineUniversity of Montréal Quebec Canada

3. Université Paris Descartes, Paris, France and M3C‐Necker, AP‐HP, Hôpital Necker‐Enfants MaladesUniversité Paris Descartes, Sorbonne Paris Cité Paris France

4. Eli Lilly Canada Inc. Toronto Ontario Canada

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14039

Reference16 articles.

1. Causes and Circumstances of Death in Pulmonary Arterial Hypertension

2. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: respondersversusnonresponders

3. Nitric oxide–cyclic GMP pathway with some emphasis on cavernosal contractility

4. Mechanisms of action of PDE5 inhibition in erectile dysfunction

5. Tadalafil Therapy for Pulmonary Arterial Hypertension

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The place of tadalafil in the treatment of PAH in the light of new clinical guidelines of the Eurasian Association of Cardiologists;Eurasian heart journal;2024-03-12

2. Neue Aspekte bei der pulmonalen Hypertonie im Kindesalter – kommentierte 2022ERS/ESC-PH-Guidelines;Pneumologie;2023-11

3. Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future;Pharmaceuticals;2023-03-28

4. Pediatric Population Pharmacokinetic Modeling and Exposure–Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data;The Journal of Clinical Pharmacology;2023-01-29

5. Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension;Pediatric Pulmonology;2022-12-28